

Ivan V Pozhidaev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7773910/publications.pdf>

Version: 2024-02-01

28
papers

227
citations

1039406

9
h-index

1058022

14
g-index

41
all docs

41
docs citations

41
times ranked

238
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 239-246.	1.3	28
2	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 687-690.	0.3	25
3	Prolactin gene polymorphism (âˆˆ 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. <i>Schizophrenia Research</i> , 2017, 182, 110-114.	1.1	24
4	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. <i>BMC Medical Genetics</i> , 2019, 20, 47.	2.1	17
5	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. <i>Frontiers in Pharmacology</i> , 2019, 10, 1462.	1.6	15
6	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of <i>CHRM1</i> and <i>CHRM2</i> muscarinic receptors. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 72-77.	1.3	13
7	NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. <i>Frontiers in Genetics</i> , 2020, 11, 936.	1.1	13
8	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1827-1835.	1.1	13
9	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. <i>Journal of Personalized Medicine</i> , 2021, 11, 181.	1.1	11
10	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 340-346.	0.9	10
11	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 63.	1.4	9
12	<p>Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia</p>. <i>The Application of Clinical Genetics</i> , 2020, Volume 13, 97-105.	1.4	7
13	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. <i>Frontiers in Psychiatry</i> , 2021, 12, 661174.	1.3	7
14	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1123-1131.	0.4	7
15	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 325-329.	1.0	6
16	No evidence so far of a major role of <i>AKT1</i> and <i>GSK3B</i> in the pathogenesis of antipsychotic-induced tardive dyskinesia. <i>Human Psychopharmacology</i> , 2019, 34, e2685.	0.7	5
17	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. <i>Human Psychopharmacology</i> , 2021, , e2826.	0.7	5
18	Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. <i>Human Psychopharmacology</i> , 2020, 35, e2737.	0.7	4

